Trial Profile
A Randomised, Controlled, Double-blind, Double-dummy, Clinical Trial Comparing Sacubitril-Valsartan Versus Valsartan in Asymptomatic, Stage A/B HFpEF Patients With Elevated Natriuretic Peptide and Abnormal LAVI. (Previously NCT02682719)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 May 2023
Price :
$35
*
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Valsartan
- Indications Cardiovascular disorders; Heart failure
- Focus Therapeutic Use
- Acronyms PARABLE
- 12 Sep 2021 Status changed from recruiting to completed.
- 10 May 2021 Planned End Date changed from 15 May 2021 to 11 Jun 2021.
- 10 May 2021 Planned primary completion date changed from 15 May 2021 to 11 Jun 2021.